pI: 6.3 |
Length (AA): 583 |
MW (Da): 66569 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 4 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
4 | 96 | 1xmw (A) | 48 | 170 | 37.00 | 0.76 | 0.93 | 0.27222 | 0.26 |
145 | 454 | 5a10 (A) | 24 | 344 | 13.00 | 0 | 1 | 0.643232 | 0.26 |
478 | 578 | 4tko (B) | 126 | 238 | 29.00 | 0.58 | 0.55 | 0.383942 | -0.5 |
514 | 580 | 3u59 (A) | 33 | 98 | 15.00 | 0.96 | 0 | 0.389323 | -1.72 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Gametocyte, 22 hs Schizont, Male gametocyte. | Otto TD Yeoh LM |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Ookinete, Female gametocyte. | Otto TD Yeoh LM |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | 4 hs Ring. | Otto TD |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 0-20% percentile | 16 hs Trophozoite, Erthyrocytic stages. | Otto TD Yeoh LM |
Yeoh LM | Comparative transcriptomics of female and male gametocytes in Plasmodium berghei and the evolution of sex in alveolates. |
Otto TD | A comprehensive evaluation of rodent malaria parasite genomes and gene expression. |
Ortholog group members (OG5_152850)
Species | Accession | Gene Product |
---|---|---|
Neospora caninum | NCLIV_028820 | hypothetical protein |
Plasmodium berghei | PBANKA_1429200 | conserved Plasmodium protein, unknown function |
Plasmodium falciparum | PF3D7_1213400 | conserved Plasmodium protein, unknown function |
Plasmodium knowlesi | PKNH_1432900 | hypothetical protein, conserved in Apicomplexan species |
Plasmodium vivax | PVX_123360 | hypothetical protein, conserved |
Plasmodium vivax | PVX_227290 | unspecified product |
Plasmodium yoelii | PY05921 | hypothetical protein |
Toxoplasma gondii | TGME49_229000 | kelch repeat-containing protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
PBANKA_1429200 this record | Plasmodium berghei | Dispensable | plasmo |
TGME49_229000 | Toxoplasma gondii | Probably non-essential | sidik |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.